Better data, not bigger models, drives accurate drug metabolism predictions: systemic lessons for AI in pharma
Original framing: “STAT+: Drug metabolism AI competition results show that bigger may not always be better” — STAT News
Rigorous benchmarking in the competition confirms that curated, high‑quality ADMET datasets improve predictive accuracy more than increasing parameter counts. The scientific community has documented diminishing returns for model scaling beyond a certain threshold, especially when training data are noisy or biased. This evidence supports a shift toward data‑centric research designs.
The competition’s headline victory masks a deeper systemic truth: data quality, not model bulk, is the decisive factor for reliable drug metabolism prediction.
Historical patterns show that periods of open data sharing outpace eras of proprietary scaling, a lesson reinforced by cross‑cultural examples where community‑owned repositories drive innovation. By foregrounding marginalized researchers, indigenous knowledge, and green AI standards, we can reconfigure the incentive architecture that currently privileges venture‑backed model expansion. Implementing FAIR data infrastructures, collaborative grant models, and regulatory incentives will align scientific rigor with equity and sustainability, turning the current hype into a durable, inclusive advance for global health.